3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lung Neoplasms
8
Colorectal Neoplasms
4
Stomach Neoplasms
3
Rectal Neoplasms
3
Prostatic Neoplasms
3
Neoplasms
3
Smoking Cessation
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Motor Activity
2
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
2
Colonic Neoplasms
2
Wilms Tumor
1
Venous Thromboembolism
1
Uveal Melanoma
1
Untreated Human Epidermal Growth Factor Receptor-2(HER2)Positive Early Breast Cancer
1
Recurrence
1
Pulmonary Disease, Chronic Obstructive
1
Opioid-Related Disorders
1
Neuroblastoma
1
Neoplastic Cells, Circulating
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Follicular
1
Leukemia, Myeloid, Acute
1
Leukemia
1
Inflammation
1
Hodgkin Disease
1
Hepatic Veno-Occlusive Disease
1
HPV Positive Oropharyngeal Squamous Cell Carcinoma
1
Fibrosis
1
Interventions
Blood Specimen Collection
9
Liquid Biopsy
4
cabazitaxel
3
Trastuzumab
3
Surgical Procedures, Operative
3
Propofol
3
Bevacizumab
3
Standard of Care
2
Spinal Puncture
2
Sevoflurane
2
Positron Emission Tomography Computed Tomography
2
Pirinitramide
2
Morphine
2
Laparoscopy
2
Folfox protocol
2
Epirubicin
2
Drug Therapy
2
Cyclophosphamide
2
Cetuximab
2
Carboplatin
2
Aspirin
2
Anesthesia, General
2
ribociclib
1
pertuzumab
1
osimertinib
1
jinfukang
1
eribulin
1
Zoledronic Acid
1
Vinorelbine
1
Thiotepa
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplastic Cells, Circulating
×
Hematologic Tests
×
Clear all
NCT02610764
2017-04-13
ESO-CTC
University Hospital Freiburg
Phase NA
Completed
19 enrolled